Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641188 | 0.92 | CHRM2 (0.56) | CHRM3CHRM2ADRB2 | |
| SCHEMBL4751486 | 0.92 | CHRM3 (0.55) | CHRM3CHRM2ADRB2 | |
| SCHEMBL642706 | 0.85 | CHRM3 (0.54) | CHRM3ADRB2 | |
| SCHEMBL643481 | 0.85 | CHRM3 (0.53) | CHRM3ADRB2 | |
| SCHEMBL1303558 | 0.84 | CHRM2 (0.63) | CHRM3CHRM2 | |
| SCHEMBL943879 | 0.84 | CHRM3 (0.58) | CHRM3 | |
| SCHEMBL1304368 | 0.82 | CHRM3 (0.55) | CHRM3CHRM2 | |
| SCHEMBL942860 | 0.82 | CHRM3 (0.59) | CHRM3 | |
| SCHEMBL943474 | 0.82 | CHRM3 (0.61) | CHRM3 | |
| SCHEMBL3543005 | 0.81 | CHRM3 (0.71) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629336-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-[2-((4-[4-(2-hydroxyethylcarbamoyl)piperidin-1-ylmethyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-08 | — | — | US | claimed |
| EP-1856112-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006099032-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 1/4885ADRB2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.